术中MRI引导切除不优于5-氨基乙酰丙酸引导在新诊断胶质母细胞瘤中的应用:一项前瞻性对照多中心临床试验
这项前瞻性对照多中心平行组试验在11个德国中心纳入314例新诊断胶质母细胞瘤患者,比较5-ALA与iMRI两组完全切除率。5-ALA组127例中90例(78%)实现完全切除(残留肿瘤≤0.175 cm³),iMRI组150例中115例(81%)实现完全切除(P=0.79),iMRI组切口-缝合时间显著更长(316 vs 215分钟,P<0.001)。两组中位无进展生存期和总生存期相当,无残留对比增强肿瘤(0 cm³)是PFS和OS的显著有利预后因素。
要点
- 5-ALA组完全切除78% vs iMRI组81%,差异无统计学意义(P=0.79)。
- iMRI组切口-缝合时间316分钟 vs 5-ALA组215分钟,显著更长(P<0.001)。
- 无残留对比增强肿瘤(0 cm³)是PFS(P<0.001)和OS(P=0.048)的显著有利预后因素。
核心结论
- 未能证实iMRI在实现完全切除方面优于5-ALA。
- 新诊断胶质母细胞瘤的神经外科干预应致力于安全的完全切除,达到0 cm³对比增强残留病灶,因为任何其他残留肿瘤体积都是PFS和OS的负面预测因素。
研究设计与样本
- 前瞻性对照多中心平行组试验,设两个中心特异性治疗组(5-ALA和iMRI),采用盲法评估。
- 在11个德国中心招募314例新诊断胶质母细胞瘤患者;按治疗分析纳入5-ALA组127例和iMRI组150例。
- 主要终点为早期术后MRI上对比增强的完全切除;由独立盲法中心化审阅术前和术后1-mm层厚MRI评估可切除性和切除范围。
- 次要终点包括无进展生存期(PFS)和总生存期(OS)、患者报告的生活质量及临床参数。
主要发现
- 完全切除(定义为残留肿瘤≤0.175 cm³)在5-ALA组90例(78%)和iMRI组115例(81%)中实现(P=0.79)。
- 切口-缝合时间iMRI组316分钟 vs 5-ALA组215分钟,iMRI组显著更长(P<0.001)。
- 两组中位PFS和OS相当。
- 无任何残留对比增强肿瘤(0 cm³)是PFS(P<0.001)和OS(P=0.048)的显著有利预后因素,尤其在甲基鸟嘌呤-DNA-甲基转移酶未甲基化肿瘤中(P=0.006)。
关键数值与推荐
- 完全切除定义为残留肿瘤≤0.175 cm³。
- 5-ALA组完全切除90例(78%) vs iMRI组115例(81%),P=0.79。
- 切口-缝合时间iMRI组316分钟 vs 5-ALA组215分钟,P<0.001。
- 无残留对比增强肿瘤(0 cm³)对PFS的P<0.001,对OS的P=0.048,在MGMT未甲基化肿瘤中对PFS的P=0.006。
临床怎么用
- 作者结论指出,新诊断胶质母细胞瘤的神经外科干预应致力于安全的完全切除,达到0 cm³对比增强残留病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prospective data suggested a superiority of intraoperative MRI (iMRI) over 5-aminolevulinic acid (5-ALA) for achieving complete resections of contrast enhancement in glioblastoma surgery. We investigated this hypothesis in a prospective clinical trial and correlated residual disease volumes with clinical outcome in newly diagnosed glioblastoma. METHODS: This is a prospective controlled multicenter parallel-group trial with two center-specific treatment arms (5-ALA and iMRI) and blinded evaluation. The primary end point was complete resection of contrast enhancement on early postoperative MRI. We assessed resectability and extent of resection by an independent blinded centralized review of preoperative and postoperative MRI with 1-mm slices. Secondary end points included progression-free survival (PFS) and overall survival (OS), patient-reported quality of life, and clinical parameters. RESULTS: We recruited 314 patients with newly diagnosed glioblastomas at 11 German centers. A total of 127 patients in the 5-ALA and 150 in the iMRI arm were analyzed in the as-treated analysis. Complete resections, defined as a residual tumor ≤0.175 cm³, were achieved in 90 patients (78%) in the 5-ALA and 115 (81%) in the iMRI arm (P = .79). Incision-suture times (P < .001) were significantly longer in the iMRI arm (316 v 215 [5-ALA] minutes). Median PFS and OS were comparable in both arms. The lack of any residual contrast enhancing tumor (0 cm³) was a significant favorable prognostic factor for PFS (P < .001) and OS (P = .048), especially in methylguanine-DNA-methyltransferase unmethylated tumors (P = .006). CONCLUSION: We could not confirm superiority of iMRI over 5-ALA for achieving complete resections. Neurosurgical interventions in newly diagnosed glioblastoma shall aim for safe complete resections with 0 cm³ contrast-enhancing residual disease, as any other residual tumor volume is a negative predictor for PFS and OS.
引用
- Roder C, Stummer W, Coburger J, et al. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. J Clin Oncol. 2023. PMID: 37335962. doi:10.1200/JCO.22.01862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。